News

Adequan® Canine in the News
MAY 2022
14
MAY 		American Regent Animal Health Partners with Arthritis Foundation to Raise Awareness of Canine Osteoarthritis
May 14, 2022 – In recognition that May is Arthritis Awareness Month, American Regent Animal Health and Adequan® Canine (polysulfated glycosaminoglycan) partnered with the Arthritis Foundation to help encourage more dog owners to speak with their veterinarians about canine osteoarthritis.
American Regent Animal Health Partners with Arthritis Foundation to Raise Awareness of Canine Osteoarthritis

Video news release featuring Adequan® Canine (polysulfated glycosaminoglycan) encourages proactive arthritis management in dogs.

LONG ISLAND, NY, May 14, 2022 – In recognition that May is Arthritis Awareness Month, American Regent Animal Health and Adequan® Canine (polysulfated glycosaminoglycan) partnered with the Arthritis Foundation to help encourage more dog owners to speak with their veterinarians about canine osteoarthritis.

Against the backdrop of the “Waggers Welcome” Walk to Cure Arthritis on Long Island, American Regent Animal Health produced a video news release to raise awareness about the importance of proactively managing dogs with arthritis. The video was shared with more than 730 million people through websites and TV stations across the nation.

“We understand that dogs get arthritis too,” said Nancy Sorbella, Community Engagement Director for the Arthritis Foundation of New York. “In the last 20 years, we’ve realized that movement is the key to feeling better, and that’s why we want to include dogs in our walks with our warriors.”

Veterinary orthopedic surgeon Dr. David Dycus, MS, CCRP, DACVS, explained to walkers and video viewers alike that osteoarthritis is a disease that can affect any dog at any age. “Once cartilage wears away completely, it can’t be restored, so it’s important to help maintain it early in the disease process,” Dr. Dycus said.

Treating canine osteoarthritis with Adequan® Canine, the only FDA-approved disease-modifying osteoarthritis drug (DMOAD), may help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage. Dr. Avi Blake, an Adequan® Canine technical services veterinarian, explained the value of treating arthritis with the DMOAD Adequan® Canine. “Adequan® Canine is different from supplements and nonsteroidal anti-inflammatory drugs because it proactively treats the disease, not just the clinical signs of canine osteoarthritis,” Dr. Blake said.

Ideally, dog owners and veterinarians will begin discussing a dog’s risk of arthritis during the first puppy visits. Veterinarians can download tools to get the conversation started and help clients learn about canine arthritis. This way, everyone can be on the lookout for signs of the disease so it can be managed early for better long-term results. After all, the goal is to keep dogs with arthritis walking for as long as possible.

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.

About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 1-800-458-0163. Adequan is a registered trademark of American Regent, Inc.
© 2022, American Regent, Inc. PP-AC-US-0442 06/2022
JUNE 2020
1
JUN 		Veterinary Practice News Cover Story Provides Clinical Insights on Managing Osteoarthritis in All Ages of Dogs and Stages of Disease
June 1, 2020 – The June 2020 issue of Veterinary Practice News featured a cover story about canine osteoarthritis (OA) written by American Regent Animal Health Advisory Board Member Denis Marcellin-Little, DEDV, DECVS, DACVS, ACVSMR, a professor of orthopedic surgery at the University of California, Davis, School of Veterinary Medicine.
Veterinary Practice News Cover Story Provides Clinical Insights on Managing Osteoarthritis in All Ages of Dogs and Stages of Disease

June 1, 2020 – The June 2020 issue of Veterinary Practice News featured a cover story about canine osteoarthritis (OA) written by American Regent Animal Health Advisory Board Member Denis Marcellin-Little, DEDV, DECVS, DACVS, ACVSMR, a professor of orthopedic surgery at the University of California, Davis, School of Veterinary Medicine. In the article, Dr. Marcellin-Little presents a comprehensive, evidence-based approach to managing osteoarthritis over a dog’s lifetime, emphasizing that early-stage OA diagnosis and intervention are key.

He writes that Stage 1 osteoarthritis likely develops in still-growing dogs and Stage 2 in young adults. Because signs are intermittent in these early stages, pet owners often dismiss them. This is why veterinary intervention is critical. Veterinarians can proactively or retroactively manage OA in the first and second stages. Proactive management protects joints from degeneration and slows the progression of OA, while retroactive management alleviates OA pain and minimizes clinical signs without impacting the true course of the disease. Dr. Marcellin-Little says proactive OA management is more effective because maintaining strength is much easier than recovering it.

The article features a chart outlining each of the four stages of OA, including the likely age of development, signs and key management strategies. Dr. Marcellin-Little also provides photos of dogs exhibiting signs of OA in each stage, and he debunks common osteoarthritis myths.

To read the complete article, you can see it at the following: June issue of VPN, or if you would like to download the article PDF to keep and read later click here. PP-AC-US-0269 8/2020
March 2020
30
MAR 		On Take a Walk in the Park Day, American Regent Animal Health Encourages Pet Owners to Get Their Dogs Moving for Healthy Joints
Melville, NY, March 30, 2020 – On National Take a Walk in the Park Day, American Regent Animal Health produced a video news release featuring animal health experts explaining how walking can help keep dogs’ joints healthy, especially when dogs are suffering from canine osteoarthritis (OA).
On Take a Walk in the Park Day, American Regent Animal Health Encourages Pet Owners to Get Their Dogs Moving for Healthy Joints
Experts share how a walk in the park can help slow the effects of canine osteoarthritis
Melville, NY, March 30, 2020 – On National Take a Walk in the Park Day, American Regent Animal Health produced a video news release featuring animal health experts explaining how walking can help keep dogs’ joints healthy, especially when dogs are suffering from canine osteoarthritis (OA). Websites and TV and radio stations across the country shared the video, with the message reaching more than 705 million people.

"There's this perception that if a dog has osteoarthritis, they shouldn’t be active,” David Dycus, DVM, MS, CCRP, Dipl. ACVS, said in the video. "In fact, walking is the best form of daily exercise. That's going to help our joints stay healthy, minimize arthritic changes, and help maintain a lean body weight while at the same time promoting great joint range of motion."

The video news release was created to help dog owners learn more about canine OA (also known as degenerative joint disease or DJD). OA is the most common cause of chronic pain in dogs.1 Thankfully, catching OA early gives dog owners the opportunity to work with their veterinarian to slow the debilitating effects.

Aired on regional TV stations and national outlets including ABC, NBC and CBS, as well as on programs such as Shark Tank (CNBC), Cuomo Prime Time (CNN) and Hannity (FOX News), the video news release helped dog owners learn how to spot the early warning signs of canine OA. Dr. Dycus, an orthopedic surgeon at Veterinary Orthopedic & Sports Medicine Group in Annapolis Junction, Md., outlined clues owners can look for while walking their dogs.

A key recommendation in the video was for dog owners and veterinarians to talk about osteoarthritis early in a dog’s life. This way, veterinarians can monitor the dog for OA and, if OA is diagnosed, recommend lifestyle changes and treatment options such as Adequan® Canine (polysulfated glycosaminoglycan), which can help slow the effects of OA. Lindsey Nichols, BA, CSCS, territory manager for American Regent Animal Health, discussed Adequan Canine in the video, explaining how it may help keep dogs with OA moving.

Adequan Canine is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) for dogs. It is proven to help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage.2 Adequan Canine is different from supplements or non-steroidal anti-inflammatory drugs (NSAIDs) because it proactively treats the disease and not just the signs of canine osteoarthritis.2

Ask your veterinarian if Adequan Canine is the right choice for your dog. For more information, visit adequancanine.com.

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequancanine.com.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. 1 Esptein M., Kirkby Shaw K. Osteoarthritis in Dogs and Cats: Novel Therapeutic Advances. 2016 NAVC Proceedings, pp. 863-865.
2 Adequan® Canine package insert, Rev 9/2021. PP-AC-US-0260 6/2020
January 2020
7
JAN 		Adequan® Canine Challenge Supports Animal Charities and Dogs with OA
Shirley, N.Y., Jan. 7, 2020 – Adequan® Canine (polysulfated glycosaminoglycan) and WoofTraxSM are partnering on the Walking is Remarkable Challenge to raise money for animal charities…
Adequan® Canine Challenge Supports Animal Charities and Dogs with OA
Turn those New Year’s fitness resolutions into walks with your dog that earn money for charity
Shirley, N.Y., Jan. 7, 2020 – Adequan® Canine (polysulfated glycosaminoglycan) and WoofTraxSM are partnering on the Walking is Remarkable Challenge to raise money for animal charities and awareness of canine osteoarthritis (OA). Simply by walking their dogs, WoofTrax app users have won donations from Adequan® Canine for 24 of their favorite charities to date. Dog walkers are also learning about the importance of early, veterinary-led management of canine OA.

The 10-week challenge promotional period lasts through Feb. 28, 2020. To participate, dog owners must join the Walking is Remarkable Challenge on the WoofTrax app, available for download from the App Store or Google Play. Walks logged in the app during the challenge count as an entry for the participant’s favorite animal charity to win one of eight weekly $25 donations and one of eight $500 grand prize awards.* In total, challenge sponsor Adequan® Canine will provide $6,000 to animal charities across the nation.

Dog owners who complete the Walking is Remarkable Challenge each week are also entered to win random weekly drawings for a $10 e-coupon from various pet-focused retailers. Winners can donate the coupon to their designated charity or get a special treat for their own fur babies. All challenge donations are provided by American Regent Animal Health, proud manufacturer of Adequan® Canine. Complete challenge details are available at wooftrax.com/caninemobility

Take steps to identify OA
While walking their dogs, Adequan® Canine encourages dog owners to watch for signs of canine OA. Look for the dog seeming stiff or slow, having trouble squatting to eliminate or hesitating to climb curbs or stairs. If these early signs are visible, it may be time to speak with a veterinarian about how to rethink OA, which can affect dogs of all ages. The foundations of the disease can begin when dogs are young and progress as they get older. Pet owners can talk with their veterinarian to discover if Adequan® Canine is right for their dog. Early diagnosis and treatment can help dogs enjoy greater mobility – and more walks – for a lifetime.

Adequan® Canine, Brand of Polysulfated Glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequancanine.com.

About WoofTrax Founded in 2013 and based in Easthampton, Mass., WoofTrax gives dog owners the chance to earn donations for their favorite local animal organization just by walking their dog. WoofTrax is one of the most used pet-focused fitness apps in the United States. Its challenges focus on pet health, letting pet owners win prizes for themselves and donations for their favorite local shelters for rescue, all while keeping their pet healthy. For more information, visit wooftrax.com.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. *Participating animal charities in the U.S. are eligible for the donation prizes. Walks greater than a quarter of a mile count in the challenge. Up to four walks per day will count towards challenge prizes and donations. PP-AC-US-0205 1/2020
August 2019
26
AUG 		On National Dog Day, American Regent Animal Health Shares an Educational Message to Help Dogs with Osteoarthritis Feel Better
New York, Aug. 26, 2019 – One day. Four hours. Two experts. On National Dog Day, American Regent Animal Health, a division of American Regent, Inc., hosted a Canine Osteoarthritis (OA) Satellite Media Tour...
On National Dog Day, American Regent Animal Health Shares an Educational Message to Help Dogs with Osteoarthritis Feel Better

New York, Aug. 26, 2019 – One day. Four hours. Two experts. On National Dog Day, American Regent Animal Health, a division of American Regent, Inc., hosted a Canine Osteoarthritis (OA) Satellite Media Tour that reached more than 750 million people across the nation. The goal was to help dog owners recognize canine OA as one of the most common diseases impacting our beloved companions and provide information to help them proactively manage the disease.

TV and radio broadcasters from regional outlets to major ABC, CBS, NBC and FOX affiliates interviewed American Regent Territory Manager, Meredith Kahn, MS, and Kristin Kirkby Shaw, DVM, MS, PhD, DACVS, ACVSMR, via satellite feed. The experts explained any dog is susceptible to OA and there is no cure. That’s why early intervention is important to help slow the clock on OA and help improve a dog’s mobility and quality of life.

“Canine arthritis can progress over time and sneak up on many dog owners,” says Dr. Kirkby Shaw, who’s also Medical Director at SOUND Veterinary Rehabilitation Center in Seattle. “Signs of arthritis are often subtle and easily overlooked or confused with normal aging, so pet owners may inadvertently wait to seek help until their dog’s symptoms are serious and debilitating.”

Talk to your veterinarian early – ideally when your dog is young so your veterinarian can screen for risks of developing arthritis. Early veterinary intervention is critical to managing osteoarthritis – in its early stages. Adequate exercise, weight management, nutritional modifications and other lifestyle adjustments may be recommended along with medication, such as Adequan® Canine (polysulfated glycosaminoglycan), which helps control signs associated with OA in a dog’s synovial joints.

Adequan Canine is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) for dogs. Adequan Canine is proven to help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage.1 Adequan Canine is different from supplements or non-steroidal anti-inflammatory drugs (NSAIDs) because it proactively treats the disease and not just the signs of canine osteoarthritis.1

Ask your veterinarian if Adequan Canine is the right choice for your dog. For more information, visit adequancanine.com.

Adequan® Canine, Brand of Polysulfated Glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. 1. Adequan® Canine package insert, Rev 9/2021. PP-AC-US-0190 8/2019
December 2018
18
DEC 		Luitpold Animal Health Becomes American Regent Animal Health January 1
18 December 2018 – Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc. manufacturer of Adequan®…
Luitpold Animal Health Becomes American Regent Animal Health January 1

Change sets the stage for company’s growth and expansion

Shirley, N.Y., Dec. 18, 2018 – Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturer of Adequan® (polysulfated glycosaminoglycan) for horses and dogs, will become American Regent Animal Health effective Jan. 1, 2019. The change reflects its commitment to animal health while unifying the company under a common set of values, goals and operating principles. Luitpold Pharmaceuticals, Inc. will streamline its operations by absorbing its wholly-owned subsidiaries, American Regent, Inc. and PharmaForce, Inc., into one corporate entity as of Dec. 31, 2018. Although Luitpold will be the surviving entity, its name will be changed to “American Regent, Inc.” following the merger.

“This change allows us to draw on the strength of the American Regent brand and U.S. manufacturing footprint to continue delivering on the promise of better solutions for the health and wellbeing of animals,” says Joel Steckler, Vice President, Commercial Operations, American Regent Animal Health. “Our commitment remains unwavering, as this evolution will position us to stay relevant to the needs of our customers and continue advancing a leading portfolio of animal health products that is anchored by Adequan.”

American Regent is a strong, well-recognized brand with 50 years of history that is best known for its human pharmaceutical products. The company is widely-known in the United States for providing high quality, trusted products for treating iron deficiency and generic specialty injectables.

“While our company name is changing, all customer service, manufacturing, sales and distribution channels will remain the same,” adds Steckler. “We will continue to provide our customers with proven products and continue to place emphasis on best-of-class service.”

Luitpold Pharmaceuticals entered the animal health market in 1984. The company released its marquis animal health product, Adequan i.m. for horses in 1989 and Adequan for dogs in 1997. The company maintains the only FDA-approved polysulfated glycosaminoglycan manufacturing site in the world. Until recently, Adequan Canine was marketed under a licensing agreement by another animal health company. In April 2018, the company brought Adequan Canine back into its portfolio, signaling its renewed commitment to animal health and additional growth in the space. Now, as American Regent Animal Health, the company will further expand its product line and seek new innovations in the animal health space to bring to market.

For customer support or to reach an American Regent Animal Health sales representative, please call 800-458-0163. For more information, visit ARAnimalHealth.com.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. NP-AI-US-0023 12/2018
April 2018
3
APR 		Adequan® Canine Returns to Luitpold Animal Health Product Portfolio
April 3, 2018 – Luitpold Animal Health, manufacturer of Adequan® (polysulfated glycosaminoglycan) for horses, today announced...
Adequan® Canine (polysulfated glycosaminoglycan) Returns to Luitpold Animal Health Product Portfolio

Manufacturer to Market and Distribute Product Beginning April 1, 2018

Shirley, N.Y., April 3, 2018 – Luitpold Animal Health, manufacturer of Adequan® (polysulfated glycosaminoglycan) for horses, today announced Adequan® Canine, a product trusted for more than 20 years by veterinarians, rejoins its portfolio of leading FDA-approved joint health products.

"As the maker of Adequan Canine, Luitpold Pharmaceuticals has stood behind Adequan Canine from the start, ensuring quality, safety and efficacy standards are met,” says Joel Steckler, vice president of commercial operations for animal health. “Equine practitioners have confidently prescribed Adequan for nearly 30 years, so while you might not have known Luitpold by name, you have seen our commitment to making a difference with proven solutions.”

Supply and distribution should remain uninterrupted during this transition. Veterinarians may continue to purchase Adequan Canine through their authorized veterinary distributor and should direct questions regarding current or pending orders to their distributor. Customer and technical support will be handled by Luitpold Animal Health.

Osteoarthritis is estimated to affect approximately 20 percent of dogs over 1 year of age , and can slowly take the joy out of life for a dog,” says Robert McCloskey, D.V.M., pharmacovigilance veterinarian. “Protecting the joint cartilage in the early stages of the disease can make a real difference in the quality of a dog’s life. Adequan Canine has advanced joint health for thousands of dogs, helping them get back to being active by controlling the signs of canine arthritis.”

Adequan Canine is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) for dogs that inhibits enzymes which break down cartilage, so joint damage is reduced. It is proven to help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage.

“We look forward to working with veterinarians to continue delivering the potential benefits of Adequan Canine for dogs suffering from osteoarthritis,” says Steckler. “And for those veterinarians who have yet to discover its potential benefits, we hope you will take this opportunity to learn more. This change reflects the beginning of a new era for this long-standing brand, as well as for the animal health division of Luitpold.”

For customer support or to reach a Luitpold Animal Health sales representative, please call 800-458-0163, Monday-Friday, 8 a.m. to 6 p.m. ET or email cs@luitpold.com. For technical questions, call medical affairs at 888-354-4855, Monday-Friday, 9 a.m. to 5 p.m. ET. To report an adverse event, call 800-734-9236 or email pv@luitpold.com. To learn more about Adequan Canine visit adequancanine.com.

IMPORTANT SAFETY INFORMATION
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. For additional safety information, please see Full Prescribing Information.

About Luitpold Animal Health
For nearly 30 years, Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., has been committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved equine polysulfated glycosaminoglycan for the intramuscular treatment of non-infectious degenerative joint disease of the carpal and hock joints, which has been relied on for nearly three decades by equine practitioners. As the manufacturer of Adequan Canine, the company recently returned marketing and distribution of the product to its portfolio, reflecting its position as a leader in joint health care for horses and dogs. Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, manufactures and distributes more than 100 human pharmaceutical products and devices, as well as innovative products for acute pain control and veterinary medicine use. The company continues to invest in its animal health portfolio as a strategic priority. For more information on Luitpold Animal Health, visit ARAnimalHealth.com or call 800- 458-0163. 1. Walton MB, Cowderoy E, Lascelles D, Innes JF (2013) Evaluation of Construct and Criterion Validity for the ‘Liverpool Osteoarthritis in Dogs’ (LOAD)Clinical Metrology Instrument and Comparison to Two Other Instruments. PLoS ONE 8(3): e58125. doi:10.1371/journal.pone.0058125
2. Adequan® Canine Prescribing Information, Rev. 1/18.
3. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141 -038 Freedom of Information Summary, 1997.
 NP-AC-US-0001 4/2018


Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

CANINE VETERINARY
PROFESSIONAL		 DOG OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up Press Room
ABOUT ADEQUAN® CANINE
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
All trademarks are the property of American Regent, Inc
© 2022, American Regent, Inc.
PP-AC-US-0102 (v6.0) 04/2022